Ovarian Cancer Tied to Bacteria Colonization of Microbiome

January 18, 2023 10:34 am

A specific colonization of microbes in the reproductive tract is commonly found in women with ovarian cancer, according to a new study from Mayo Clinic’s Center for Individualized Medicine. The discovery, published in Scientific Reports, strengthens evidence that the … Read more

Acupuncture, acupressure may benefit women undergoing gynecologic cancer surgery

January 17, 2023 10:20 am

by Jennifer Southall

Women who underwent surgery for gynecologic cancers experienced decreased symptoms of anxiety and pain with the use of acupressure before surgery and acupuncture during surgery, according to study results published in Cancer.

Further investigation is needed … Read more

Luveltamab Tazevibulin Shows Encouraging Activity in Frα-Selected Advanced Ovarian Cancer

January 16, 2023 10:07 am

by Caroline Seymour

Treatment with the folate receptor α–directed antibody-drug conjugate luveltamab tazevibulin led to a 37.5% overall response rate in Frα-selected patients with advanced ovarian cancer, defined by a tumor proportion score above 25%.

Treatment with the folate receptor

Read more

Targeting FRα Enters a New Era in Ovarian Cancer and Beyond

January 16, 2023 9:41 am

by Anita T. Shaffer

Efforts to target the folate metabolism network have entered a new stage, with the approval of a novel therapy directed at folate receptor–α and the potential for additional agents aimed at that target in solid tumors.Read more

COM701 Plus BMS-986207/Nivolumab Shows Early Activity in Platinum-resistant Ovarian Cancer

January 12, 2023 10:08 am

by Ryan Scott

A triplet regimen comprised of COM701, BMS-986207, and nivolumab was found to have encouraging antitumor activity and favorable tolerability in patients with heavily pretreated, platinum-resistant ovarian cancer.

A triplet regimen comprised of COM701, BMS-986207, and nivolumab (Opdivo)

Read more

Genetic Test Identifies Ovarian Cancer Patients Likely To Benefit From PARP Inhibitors

January 12, 2023 9:58 am

A genetic test developed in a study at the University of Helsinki and Helsinki University Hospital identifies ovarian cancer patients who benefit from PARP inhibitors, a treatment option.

Since the therapy is associated with potential serious side-effects, it is important … Read more

Yale Cancer Center Research Helps Expand NCCN Guidelines for Ovarian Cancer

January 5, 2023 10:50 am

by Eliza Folsom

Results from a recent Yale Cancer Center Phase II trial studying ixabepilone and bevacizumab vs ixabepilone alone in platinum resistant ovarian cancer patients have led to the combination added as a Category 2B recommended regimen in Ovarian … Read more

Watch for New Psych Disorders in the Spouses of Cancer Patients

January 5, 2023 10:44 am

— Risk especially high within the first year after cancer diagnosis

by Kristen Monaco

Clearity offers psychosocial support through our Steps Through OC program for patients, survivors and caregivers. If you would like personal one-to-one assistance with the stress and Read more

Racial, ethnic minority groups lack representation in OB/GYN trials

January 4, 2023 10:23 am

by Kalie VanDewater

Reporting of race and ethnicity data and representation of different racial and ethnic populations in OB/GYN clinical trials are subpar, although improvement is possible, according to findings published in JAMA Surgery.

“Although trial results inform policies … Read more

Guideline addresses use of integrative therapies for cancer-related pain management

November 30, 2022 3:07 pm

by Jennifer Byrne

A new clinical practice guideline jointly published by ASCO and Society for Integrative Oncology addresses the potential role of integrative pain management techniques in management of cancer-related pain in adults.

“Patients with cancer, as well as cancer … Read more

Race, Ethnicity ‘Notably Underreported’ in Publicly Accessible Databases of Gynecologic Cancer Trials

November 29, 2022 2:29 pm

by Nicolas Wrigley

Findings from a recent 30-year analysis of more than 1,000 gynecologic cancer trials strongly suggest that reporting race and ethnicity must be a required part of clinical research to improve diversity, according to a group of researchers.Read more

Machine learning model builds on imaging methods to better detect ovarian lesions

November 29, 2022 11:37 am
by Beth Miller
(From left) The top row shows an ultrasound image of a malignant lesion, the blood oxygen saturation, and hemoglobin concentration. The bottom row is an ultrasound image of a benign lesion, the blood oxygen saturation, and hemoglobin
Read more

‘Disenchanted’ Star And Passionate Cancer Advocate Patrick Dempsey Reminds Caregivers To ‘Take Care Of Yourself’

November 26, 2022 2:29 pm

by Teaganne Finn

Actor Patrick Dempsey, 56, has a warm message for all the cancer caregivers— take care of yourself, too. The Greys Anatomy star knows first hand how taxing it can be as a caregiver for a sick loved … Read more

FDA Seeks to Restrict Rucaparib to Second-line Maintenance Therapy in Recurrent Ovarian Cancer

November 18, 2022 11:51 am

by Jason Harris

The FDA has asked Clovis Oncology to limit use of rucaparib (Rubraca) to second-line maintenance therapy for patients with recurrent ovarian cancer harboring BRCA mutations.1

The company is considering the FDA’s request. If the 2 sides

Read more

FDA Approves Mirvetuximab Soravtansine-gynx for FRα+ Platinum-resistant Ovarian Cancer

November 14, 2022 12:21 pm

By Kristi Rosa

The FDA has granted accelerated approval to mirvetuximab soravtansine-gynx (Elahere) for the treatment of adult patients with folate receptor α (Frα)–positive, platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer, who have received 1 to 3 prior … Read more

FDA Requests Restriction of Second-line Maintenance Niraparib Indication in Ovarian Cancer

November 14, 2022 11:41 am

by Kristi Rosa

At the request of the FDA, GlaxoSmithKline (GSK) plc will restrict the second-line maintenance indication for niraparib (Zejula) to only the population of patients with recurrent ovarian cancer whose tumors harbor deleterious or suspected deleterious germline BRCA

Read more

Penn Study Illuminates Why Cancers Caused by BRCA Mutations Recur

November 10, 2022 11:36 am

Findings uncover possible drivers of recurrent breast and ovarian cancers among women carrying high-risk genetic mutations, pointing to methods to more effectively treat disease

PHILADELPHIA — Researchers at the University of Pennsylvania’s Basser Center for BRCA at the Abramson Cancer … Read more

Black women less likely to receive guideline-concordant therapy for ovarian cancer

November 9, 2022 11:23 am

by Matthew Shinkle

Black women in the U.S. appeared less likely than white women to receive guideline-concordant treatment for ovarian cancer, according to a study published in Journal of the National Comprehensive Cancer Network.

Even among white women, the … Read more

Restoring the gut biome after antibiotics could lead to better outcomes for ovarian cancer patients

November 8, 2022 11:09 am

by Cleveland Clinic

Reassessing antibiotic dosage and type could improve survival rates in deadliest gynecologic malignancy, Cleveland Clinic research finds

Newswise — CLEVELAND – Antibiotics routinely used in ovarian cancer care indiscriminately kill gut bacteria, leading to faster cancer progression … Read more

Preventing Chemo Brain? Study Identifies Potential Approach for Common Problem

November 2, 2022 4:22 pm

by NCI Staff

A side effect of some cancer treatments commonly referred to as “chemo brain” has received increasing attention from researchers in recent years. Often referred to as cancer-related cognitive impairment, chemo brain can be marked by severe memory … Read more